Clinical Trial Update: Sodium Butyrate For Improving Cognitive Function In Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial of sodium butyrate for improving cognitive function in schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Sodium butyrate (sodium butyrate)

Snippet

Sponsor: Nathan Kline Institute for Psychiatric Research | Conditions: Schizophrenic Disorders, Cognitive Function | Phase 2, Phase 3 | Status: WITHDRAWN